All filters
Slidesets
Novel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts NAS score for NASH diagnosis- Alina Allen
Presented at:
International Workshop on NASH Biomarkers 2017
Slidesets
Big data vs. the individual liver - regulatory perspective- Robert Schuck, PharmD, PhD
Presented at:
International Workshop on NASH Biomarkers 2017
Slidesets
Serum GP73 as a surrogate biomarker of significant liver fibrosis and cirrhosis in NAFLD- Fengmin Lu
Presented at:
International Workshop on NASH Biomarkers 2017
Slidesets
Future scenarios of algorithm building- Tom Travison, PhD
Presented at:
International Workshop on NASH Biomarkers 2017
Slidesets
A precision medicine approach to comprehensive NAFLD diagnosis via metabolomics-based liquid biopsy- Pablo Ortiz
Presented at:
International Workshop on NASH Biomarkers 2017
Slidesets
Next-Generation Sequencing (NGS) of two independent cohorts identifies eleven circulating miRNAs for diagnosis of NASH and fibrosis- Sven Francque
Presented at:
International Workshop on NASH Biomarkers 2017
Slidesets
Navigating NASH biomarkers: From discovery to clinical practice- John Sninsky, PhD
Presented at:
International Workshop on NASH Biomarkers 2017
Slidesets
Integrated assessment of diabetes, cardiovascular and liver risks and its potential application in the clinical management of NAFLD- Arun Sanyal, MD, MBBS
Presented at:
International Workshop on NASH Biomarkers 2017
Slidesets
Can Bariatric surgery convert a non-candidate to a candidate? - Julie Heimbachx, MD
Presented at:
Symposium on Key Issues in Liver Transplantation for NASH 2016
Slidesets
What is an acceptable BMI - Lee Kaplan, MD, PhD
Presented at:
Symposium on Key Issues in Liver Transplantation for NASH 2016
Slidesets
How should we optimize immunosuppression? - Kittie Wynne, MD, PhD
Presented at:
Symposium on Key Issues in Liver Transplantation for NASH 2016
Slidesets
Methods of MR fat quantification and their pros and cons | Michael Middleton, MD, PhD
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
Noninvasive imaging methods for assessment of liver damage in NASH | Bachir Taouli, MD
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
NASH and Fibroscan | Raj Vuppalanchi, MD
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
O_04 - Blood-based Protein Biomarkers of NASH | Dr. S. Williams
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
O_05 - Validation of multiparametric MRI in the assessment and staging of non-alcoholic fatty liver disease | Dr. P. Eddowes
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
LiverMultiScan – quantitative MR imaging for NASH | Rajarshi Banerjee
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
O_06 - Longitudinal changes in FIB-4 and improvement in fibrosis stage with obeticholic acid: A secondary analysis of FLINT Trial | Dr. A. Sanyal
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
Need for Biomarker Development in Non-Alcoholic Fatty Liver Disease | Eric Lefebvre, MD
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
Principles of Biomarker Development | Margery Connelly, PhD, MBA
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
Quantitative measures of liver health | Grey Everson, MD
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
Defining the gold standard in Biomarker Validation in NAFLD | Arun Sanyal, MD, MBBS
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
O_02 - Performance of non-invasive tests in the staging of fibrosis in patients with NAFLD: interim results of a prospective multicentre study | Dr. P. Eddowes
Presented at:
International Workshop on NASH Biomarkers 2016